FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed is peroral pharmaceutical composition for treatment of urinary retention, caused by opioids, which includes, at least, one opioid antagonist naloxone or its pharmaceutically acceptable salt (versions).
EFFECT: disclosed is achievement of claimed intention, with naloxone possessing very low peroral bioavailability, and does not prevent (does not reverse) pain-killing action of opioid agonist.
17 cl, 19 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| OXICODON AND NALOXON-CONTAINING PHARMACEUTICAL COMPOSITIONS WITH INSTANT RELEASE | 2010 |
|
RU2522212C2 |
| COMPOSITIONS AND METHOD FOR RELIEVING RESPIRATORY DISTRESS CAUSED BY OPIOID OVERDOSE | 2011 |
|
RU2541159C2 |
| INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE | 2012 |
|
RU2657441C1 |
| PHARMACEUTICAL COMPOSITIONS | 2007 |
|
RU2445077C2 |
| COMPOSITIONS AND METHODS OF TREATING OPIOID OVERDOSE | 2017 |
|
RU2769397C2 |
| INTRANASAL PHARMACEUTICAL DOSAGE FORMS COMPRISING NALOXONE | 2012 |
|
RU2587051C2 |
| COMPOSITIONS, DEVICES AND METHODS FOR THE TREATMENT OF ALCOHOL DEPENDENCE | 2017 |
|
RU2767062C2 |
| APPLICATION OF BINDING AGENTS TO OBTAIN STABLE IN STORAGE COMPOSITIONS | 2011 |
|
RU2572695C2 |
| DRUG FORM CONTAINING OXYCODON AND NALOXON | 2006 |
|
RU2428985C2 |
| APPLICATION OF ANTAGONISTS OF OPIOID RECEPTORS IN CASE OF GASTROINTESTINAL TRACT DISEASES | 2010 |
|
RU2561873C2 |
